All In MedTech

FDA Clearance Tracker · P130021-S051

CoreValve Evolut R System and CoreValve Evolut PRO System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 24, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P130021-S051
Device name
CoreValve Evolut R System and CoreValve Evolut PRO System
Applicant location
Miinneapolis, MN
Received
Jun 29, 2018
Decided
Aug 24, 2018
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130021

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for modifying the labeling to remove the precaution regarding patients with a congenital bicuspid aortic valve.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.